Tricuspid Edge-to-Edge Repair: One-Year Evolution

Tricuspid Edge-to-Edge Repair has emerged as a promising alternative to surgical repair. Different studies have shown it is safe, reducing tricuspid regurgitation and effectively improving quality of life at 12 months. 

Even though these are preliminary studies and have not shown long term benefits yet, we see promising present outcomes. 

The bRIGHT study included 511 patients with tricuspid regurgitation undergoing edge-to-edge repair with TriClip. Mean age was 79, and 56% were women, 80% were in functional class III/IV, 23% had a pacemaker, AICD or resynchronization therapy, 40% had been hospitalized at least once in the past year and 40% presented kidney function deterioration. 

In 90% of cases, TR was secondary. The most frequent was massive (61%), followed by torrential (27%) and, in lower number, severe. 

Mean ejection fraction was 56%, with a coaptation gap of 6.49 mm, RV TAPSE 1.7, and right atrial volume 156 ml.

Read also: DIRECT TAVI: Is Predilation Important for Women?

At one-year follow-up, all-cause mortality was 15.1%, cardiac death 8.8%, hospitalization for cardiac failure 15.3%, new kidney function deterioration 5.5%, and need for pacemaker implantation 0.85%.

There was sustained reduction of tricuspid regurgitation to ≤ moderate in 81% of patients, with improved functional class and quality of life.

Conclusion
Tricuspid edge-to-edge repair TriClip resulted safe and effective at one year follow-up in patients with significant tricuspid regurgitation and advanced disease, according to real world data. 

Original Title: Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair. From the bRIGHT Study

Reference: Philipp Lurz, et al. J Am Coll Cardiol 2024;84:607–616.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

Más artículos de este Autor

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Artículos relacionados

Jornadas SOLACIspot_img

Artículos recientes

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...